Lu Xiaobo, Partner of Sequoia China

Lu Xiaobo focuses on investments in the healthcare sector. He has more than 25 years of experience in this industry, and has led more than 30 investments, including BGI (300676), Betta Pharmaceuticals(300558), Innovent Biology(01801 HK), Chipscreen(688321), Nanomicro Technology (688690),

BAHEAL Pharmaceutical Group(301015), TINAVI(688277), Allgens Medical Technology(688613), KONRUNS( 603590), Shukun Technology, FAPON, INNOVITA, dMed biopharmaceutical, Shulan Health, BirdoTech, SIFARY, etc. Mr. Lu holds a bachelor's degree in Biochemical Engineering from Zhejiang University, an international MBA from Tsinghua University, and an EMBA in Finance from Tsinghua PBCSF.